Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YIC
- Development stage
- Unknown
- Lead developer
- Chinese Academy of Medical Sciences Peking Union Medical College
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
YIC is a therapeutic vaccine for chronic hepatitis B, composed of hepatitis B surface antigen (HBsAg) and hepatitis B immunoglobulin (HBIG) in an immune complex. Often yeast-derived, it aims to break immune tolerance to HBV by modulating viral antigen processing and presentation, thereby stimulating the host's immune response against the virus.
- Other names
- HBsAg-HBIG immune complex therapeutic vaccineHBsAg-HBIG immunogenic complexYeast-derived Immune Complexes
02
Targets
HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on YIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YIC.